4DMT.png
4D Molecular Therapeutics Appoints Carolyne Zimmermann as Chief Business Officer
June 07, 2021 07:00 ET | 4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene...
4DMT.png
4D Molecular Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
June 03, 2021 07:00 ET | 4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene...
4DMT.png
4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights
May 13, 2021 16:03 ET | 4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene...
4DMT.png
4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DME
May 12, 2021 17:30 ET | 4D Molecular Therapeutics, Inc.
4D-150 designed as an intravitreal gene therapy with dual transgenes expressing aflibercept and VEGF-C RNAi for the treatment of wet AMD and DMEPreclinical NHP studies of 4D-150 demonstrated...
4DMT.png
4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution Platform
May 04, 2021 16:02 ET | 4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene...
4DMT.png
4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Conference
April 30, 2021 07:05 ET | 4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene...
4DMT.png
4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from Non-Human Primate Studies
April 27, 2021 16:31 ET | 4D Molecular Therapeutics, Inc.
- Abstracts on 4D-150 for wet AMD/DME and 4D-310 for Fabry disease accepted for oral presentations at ASGCT 24th Annual Meeting - Abstract on 4D-710 for cystic fibrosis lung disease accepted for oral...
4DMT.png
4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights
March 25, 2021 16:02 ET | 4D Molecular Therapeutics, Inc.
- First patient dosed in the 4D-310 Phase 1/2 clinical trial in Fabry disease - Intravitreal product candidates, 4D-125 for the treatment of XLRP and 4D-110 for the treatment of choroideremia,...
4DMT.png
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fabry Disease
March 09, 2021 08:03 ET | 4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: 4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene...
4DMT.png
4D Molecular Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 15, 2020 16:05 ET | 4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene...